NCT00145444View on ClinicalTrials.gov

Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

November 30, 2005

Conditions
SchizophreniaPsychotic Disorders
Interventions
DRUG

olanzapine

DRUG

ziprasidone

Trial Locations (7)

B-2060

Pfizer Investigational Site, Antwerp

B-2570

Pfizer Investigational Site, Duffel

B-3070

Pfizer Investigational Site, Kortenberg

NL-3851 PB

Pfizer Investigational Site, Ermelo

NL-9713 GZ

Pfizer Investigational Site, Groningen

NL-6525 GC

Pfizer Investigational Site, Nijmegen

3584 CX

Pfizer Investigational Site, Utrecht

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00145444 - Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study | Biotech Hunter | Biotech Hunter